Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Hydralazine × Other solid neoplasm × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 4 Other solid neoplasm 1 Breast 1

Conditions

Refractory Solid Tumors 1

Interventions

pembrolizumab 2 fludarabine 2 apatinib 2 Interleukin-2 2 Cyclophosphamide 2 spartalizumab 1 phosphorylethanolamine 1 olaparib 1 liposomal doxorubicin 1 ivarmacitinib 1 camrelizumab 1 anlotinib 1 Valproic Acid 1 Topotecan 1 Talc 1 Pharmaceutical Services 1 Injections 1 Hydralazine 1 Cisplatin 1 Cerebral Decortication 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00404508 2006-11-28

A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors

National Institute of Cancerología

Phase 2 Completed

Other solid neoplasm

Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡